Gilead secures global access to remdesivir via generic manufacturing deals

The first manufacturing deals for Gilead’s remdesivir, plus a series of grants for institutions across Europe to develop COVID-19 diagnostics and therapeutics, highlight the importance of global collaboration to tackle the pandemic.

Gilead Sciences Inc. (NASDAQ:GILD) on Tuesday signed non-exclusive voluntary licensing agreements with five companies in India and Pakistan to manufacture remdesivir for distribution in 127 countries, nearly all low- and lower-middle income...